Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY-NCInternational journal of nanomedicine

Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer.

  • Manling Du1,2,3,4,5
  • Fengjie Liu1,2,3,4,6
  • Panpan Wang7
  • Mulazim Hussain Asim8
  • Qian Liu1,2,3,4,5
  • Qianwen Li1,2,3,4,5
  • Mengjie Xie1,2,3,4,5
  • Kewei Zhang1,2,3,4,5
  • Zhenjiang Yang9
  • Yu Cai1,2,3,4,5
9 affiliations
  1. 1State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, People's Republic of China.
  2. 2International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, People's Republic of China.
  3. 3Guangdong Key Laboratory of Traditional Chinese Medicine Informatization, Jinan University, Guangzhou, People's Republic of China.
  4. 4International Science and Technology Cooperation Base of Guangdong Province, Jinan University, Guangzhou, People's Republic of China.
  5. 5School of Pharmacy, Jinan University, Guangzhou, People's Republic of China.
  6. 6School of Traditional Chinese Medicine, Jinan University, Guangzhou, People's Republic of China.
  7. 7Department of Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, People's Republic of China.
  8. 8College of Pharmacy, University of Sargodha, Sargodha, Pakistan.
  9. 9Department of Oncology and Hematology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, People's Republic of China.
Read full textPDFDOICite

Abstract

Purpose

To overcome dose-limiting toxicity and paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC) therapy, as well as the asynchronous in vivo biodistribution of PTX and psoralen (PSO) combination regimens, we developed a highly biocompatible, magnetically targeted nano-co-delivery system.Methods

Paclitaxel/psoralen-loaded magnetic composite nanoparticles (P/P-TCNs) were fabricated via nanoprecipitation. The nanocarriers comprise a poly(lactic-co-glycolic acid) (PLGA) core co-encapsulating both therapeutic agents and superparamagnetic iron oxide nanoparticles (SPIONs), shielded by a stabilizing outer phospholipid layer.Results

Physiochemically, P/P-TCNs exhibited uniform nanoscale dimensions, a negative surface charge, robust superparamagnetism, and synchronized drug release profiles. In vitro, P/P-TCNs significantly enhanced intracellular drug accumulation in 4T1 murine breast cancer cells, inducing profound G2/M cell cycle arrest and augmented apoptotic response. In vivo live imaging of tumor-bearing mice revealed that under an external magnetic field, P/P-TCNs selectively and efficiently accumulated at the tumor site via tail vein injection. This magnetically guided co-delivery achieved a potent tumor inhibition rate of >85%, significantly outperforming both the free drug combination and non-targeted nanoparticle controls. Furthermore, the nanoplatform demonstrated excellent hemocompatibility (<5% hemolysis) and negligible systemic toxicity in major organs.Conclusion

P/P-TCNs facilitate the synchronized, safe, and highly efficient co-delivery of PTX and PSO. By maximizing nanocarrier‑facilitated combinatorial anti-TNBC efficacy while minimizing off-target toxicity, this biocompatible magnetic nanoplatform represents a promising translational strategy for the clinical management of refractory TNBC.

Related

  1. Ultrasmall Superparamagnetic Fe3O4 Nanoparticles Green-Synthesized with Cosmos caudatus : Phytochemical Surface Coordination and Suppression of MCF-7 Migration
    Abubakar Usman Lawal, Nik Noor Ashikin Nik Ab Razak, Farhank Saber Braim +2
    ACS OmegaPeer-reviewedCC BY 4.0Full textGeneral chemistryCrossref
  2. Theranostic silica nanoparticles for selective and simultaneous delivery of paclitaxel and coumarin to hypoxic tumors
    Paula Rodrigo-Martínez, Lamiaa Mohamed Ahmed Ali, Carmen Coll +5
    International Journal of PharmaceuticsPeer-reviewedCC BY-NC-NDMaterials & polymersHAL
  3. Pluronic F-127-functionalized magnetic ternary hybrid nanoparticles for co-delivery of paclitaxel and psoralen: a synergistic strategy to overcome multidrug resistance in triple-negative breast cancer
    Qian Liu, Fengjie Liu, Panpan Wang +8
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textMaterials & polymersCrossrefPMC
  4. Plasmon-Enhanced Nanosensing: From Single Proteins to Therapeutic Nanoparticles
    Subrat Bastola
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
  5. Molecular design and therapeutic applications of polymeric nanoparticles for drug delivery: A comprehensive review
    Sumeer Ahmed, Mohd Hasan Mujahid, Mandeep Kour +6
    Results in ChemistryPeer-reviewedCC BY-NC-ND12 citedMaterials & polymersOpenAlex

Cite

BibTeXRIS
BibTeX
@article{du2026combination,
  title = {{Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer.}},
  author = {Manling Du and Fengjie Liu and Panpan Wang and Mulazim Hussain Asim and Qian Liu and Qianwen Li and Mengjie Xie and Kewei Zhang and Zhenjiang Yang and Yu Cai},
  journal = {International journal of nanomedicine},
  year = {2026},
  month = oct,
  doi = {10.2147/ijn.s641922},
  url = {https://europepmc.org/article/MED/42904218},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
AU  - Manling Du
AU  - Fengjie Liu
AU  - Panpan Wang
AU  - Mulazim Hussain Asim
AU  - Qian Liu
AU  - Qianwen Li
AU  - Mengjie Xie
AU  - Kewei Zhang
AU  - Zhenjiang Yang
AU  - Yu Cai
PY  - 2026
DA  - 2026/10/16
JO  - International journal of nanomedicine
DO  - 10.2147/ijn.s641922
UR  - https://europepmc.org/article/MED/42904218
AB  - Purpose  To overcome dose-limiting toxicity and paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC) therapy, as well as the asynchronous in vivo biodistribution of PTX and psoralen (PSO) combination regimens, we developed a highly biocompatible, magnetically targeted nano-co-delivery system.Methods  Paclitaxel/psoralen-loaded magnetic composite nanoparticles (P/P-TCNs) were fabricated via nanoprecipitation. The nanocarriers comprise a poly(lactic-co-glycolic acid) (PLGA) core co-encapsulating both therapeutic agents and superparamagnetic iron oxide nanoparticles (SPIONs), shielded by a stabilizing outer phospholipid layer.Results  Physiochemically, P/P-TCNs exhibited uniform nanoscale dimensions, a negative surface charge, robust superparamagnetism, and synchronized drug release profiles. In vitro, P/P-TCNs significantly enhanced intracellular drug accumulation in 4T1 murine breast cancer cells, inducing profound G2/M cell cycle arrest and augmented apoptotic response. In vivo live imaging of tumor-bearing mice revealed that under an external magnetic field, P/P-TCNs selectively and efficiently accumulated at the tumor site via tail vein injection. This magnetically guided co-delivery achieved a potent tumor inhibition rate of >85%, significantly outperforming both the free drug combination and non-targeted nanoparticle controls. Furthermore, the nanoplatform demonstrated excellent hemocompatibility (<5% hemolysis) and negligible systemic toxicity in major organs.Conclusion  P/P-TCNs facilitate the synchronized, safe, and highly efficient co-delivery of PTX and PSO. By maximizing nanocarrier‑facilitated combinatorial anti-TNBC efficacy while minimizing off-target toxicity, this biocompatible magnetic nanoplatform represents a promising translational strategy for the clinical management of refractory TNBC.
SN  - 1176-9114
SN  - 1178-2013
ER  -